14/03/2017
Scientific study was conducted using a United States based team. In 1994, Dr. Jane Gibson of the Orlando Florida based Health Sciences Center started testing the OrPro in vivo (with live animals) and in vitro (with cell culture study) with the coordination of Rutgers University chemist Dr. Thomas G. Hartman and our chemist professor David Kinder.
After 14 months of comprehensive Chemical Characterization and testing of the Or Pro extract, Dr. Gibson concluded that compound inhibits the growth of the type of cells involved in . Dr. Hartman concluded that Or Pro was novel. They indicated that prospects for future development were encouraging.
We then started additional studies. A toxicity study took more than two years and indicated no toxicity whatsoever. Our chemist, Professor David Kinder started the formulation, standardization and stability process for the compound, at the Ohio University College of Pharmacy. Two clinical trials were conducted, one by Taro Pharmaceuticals, in New York, in 2004; the second by Dr. Howard Yanofsky, a Canadian dermatologist, in 2004. Both indicated a high rate of success.
To date, thousands patients have been treated with a success rate of more than 75%. ** OrPro try us > http://orproskin.com **
